In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions affect the broader population. This IVI brief uses the OSVP model for rheumatoid arthritis to illustrate how insurance value may be estimated and explore its potential implications for value assessment.
Read the full press release here.
